We are live on ! Find out more
CPX

Canaan Partners XI Portfolio holdings

AUM $127M
1-Year Est. Return 217.49%
This Fund
S&P 500
This Quarter Est. Return
-21.02%
1 Year Est. Return
+217.49%
3 Year Est. Return
+1,311.52%
5 Year Est. Return
10 Year Est. Return
AUM
$77.3M
AUM Growth
-$40.8M
Cap. Flow
-$4.4M
Cap. Flow %
-5.69%
Top 10 Hldgs %
100%
Holding
3
New
Increased
Reduced
2
Closed

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
TYRA icon
Tyra Biosciences
TYRA
+$4.18M
2
RLYB icon
Rallybio
RLYB
+$223K

Sector Composition

Rank Sector Weight
1 Healthcare 77.28%
2 Technology 22.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
TYRA icon
1
Tyra Biosciences
TYRA
$1.91B
$58.1M 75.17%
4,179,857
-230,134
-5% -$4.18M
AEVA
2
Aeva Technologies
AEVA
$1.26B
$17.6M 22.72%
3,697,039
RLYB icon
3
Rallybio
RLYB
$84.6M
$1.63M 2.11%
212,211
-26,662
-11% -$223K

Similar funds

Canaan Partners XI's Q4 2024 Portfolio in Review

As of Q4 2024, Canaan Partners XI held 3 positions worth $77.3M, down 35% from $118M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Canaan Partners XI withdrew a net $4.4M in Q4 2024, reducing 2 holdings. Its largest reduction was Tyra Biosciences, cutting an estimated $4.18M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, down from 90% a quarter earlier, followed by Technology.

  • Canaan Partners XI's biggest Q4 2024 reduction was Tyra Biosciences, cutting an estimated $4.18M.
  • Canaan Partners XI's ten largest holdings make up 100% of its $77.3M portfolio in Q4 2024.
  • Canaan Partners XI opened 0 new positions and closed 0 in Q4 2024.
  • Canaan Partners XI's portfolio value fell 35% quarter-over-quarter to $77.3M.

Based on Canaan Partners XI's 13F filing for Q4 2024, filed 21 Jan 2025.